BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016; Epub ahead of print. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Cited by in Crossref: 230] [Cited by in F6Publishing: 187] [Article Influence: 46.0] [Reference Citation Analysis]
Number Citing Articles
1 Oswari H, Rahayatri TH, Soedibyo S. Pediatric Living Donor Liver Transplant in Indonesia's National Referral Hospital. Transplantation 2020;104:1305-7. [PMID: 32568998 DOI: 10.1097/TP.0000000000003154] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol 2021:S0168-8278(21)01957-7. [PMID: 34343613 DOI: 10.1016/j.jhep.2021.07.027] [Reference Citation Analysis]
3 Boyd A, Cain O, Chauhan A, Webb GJ. Medical liver biopsy: background, indications, procedure and histopathology. Frontline Gastroenterol 2020;11:40-7. [PMID: 31885839 DOI: 10.1136/flgastro-2018-101139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
4 Neil DA, Bellamy CO, Smith M, Haga H, Zen Y, Sebagh M, Ruppert K, Lunz J, Hübscher SG, Demetris AJ. Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue. Human Pathology 2018;73:144-55. [DOI: 10.1016/j.humpath.2017.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhou S, Mitsinikos T, Emamaullee J, Weaver C, Wang L, Shillingford N, Warren M, Bawab JH, Tiwari N, Genyk Y, Thomas D, Parham DM. Clinicopathologic Characteristics of Late Acute Antibody-mediated Rejection in Pediatric Liver Transplantation. Transplantation 2021;105:2045-53. [PMID: 33031223 DOI: 10.1097/TP.0000000000003469] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tajima T, Hata K, Haga H, Nishikori M, Umeda K, Kusakabe J, Miyauchi H, Okamoto T, Ogawa E, Sonoda M, Hiramatsu H, Fujimoto M, Okajima H, Takita J, Takaori-Kondo A, Uemoto S. Post-transplant Lymphoproliferative Disorders After Liver Transplantation: A Retrospective Cohort Study Including 1954 Transplants. Liver Transpl 2021;27:1165-80. [PMID: 33655645 DOI: 10.1002/lt.26034] [Reference Citation Analysis]
7 Götz JK, Kiene H, Goldschmidt I, Junge N, Pfister ED, Leiskau C, Brown RM, Immenschuh S, Baumann U. Current Evidence on the Clinical Relevance of Donor-specific Antibodies in Paediatric Liver Transplantation. J Pediatr Gastroenterol Nutr 2021;72:788-93. [PMID: 33908737 DOI: 10.1097/MPG.0000000000003127] [Reference Citation Analysis]
8 Irie R, Nakazawa A, Sakamoto S, Takeda M, Yanagi Y, Shimizu S, Uchida H, Fukuda A, Kasahara M. Outcome for Pediatric Recipients of Macrosteatotic Liver Grafts From Living Donors. Liver Transpl 2020;26:899-905. [PMID: 32314485 DOI: 10.1002/lt.25784] [Reference Citation Analysis]
9 Honda M, Sugawara Y, Kadohisa M, Shimata K, Sakisaka M, Yoshii D, Uto K, Hayashida S, Ohya Y, Yamamoto H, Yamamoto H, Inomata Y, Hibi T. Long-term Outcomes of ABO-incompatible Pediatric Living Donor Liver Transplantation. Transplantation. 2018;102:1702-1709. [PMID: 29620615 DOI: 10.1097/tp.0000000000002197] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
10 Riva N, Dip M, Halac E, Cáceres Guido P, Woillard JB, Licciardone N, Chan D, Buendía J, Borgnia D, Bosaleh A, de Davila MT, Imventarza O, Schaiquevich P. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. Ther Drug Monit 2018;40:401-10. [PMID: 29621122 DOI: 10.1097/FTD.0000000000000517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
11 Vargas PA, Cullen JM, Argo C, Henry Z, Stotts MJ, Intagliata N, Northup P, Oberholzer J, Pelletier S, Goldaracena N. Liver Transplantation With Grafts From Super Obese Donors. Transplant Direct 2021;7:e770. [PMID: 34557587 DOI: 10.1097/TXD.0000000000001225] [Reference Citation Analysis]
12 Nakamura T, Yoshimura N, Akioka K, Shirouzu T, Kawai S, Imanishi Y, Matsuyama T, Harada S, Nobori S, Ushigome H. Clearance of Intra-graft Donor Specific Anti-HLA Antibodies in the Early Stage of Antibody-Mediated Rejection Following Rituximab and Apheresis Therapy in Renal Transplantation. Transplant Proc 2019;51:1365-70. [PMID: 31056246 DOI: 10.1016/j.transproceed.2019.01.126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Del Bello A, Congy-Jolivet N, Audry B, Antoine C, Esposito L, Hebral AL, Kamar N. Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. Liver Transpl 2017;23:880-6. [PMID: 28477360 DOI: 10.1002/lt.24781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Torbenson M, Washington K. Pathology of liver disease: advances in the last 50 years. Hum Pathol 2020;95:78-98. [PMID: 31493428 DOI: 10.1016/j.humpath.2019.08.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ip S, Bhanji RA, Ebadi M, Mason AL, Montano-Loza AJ. De novo and recurrent liver disease. Best Pract Res Clin Gastroenterol 2020;46-47:101688. [PMID: 33158472 DOI: 10.1016/j.bpg.2020.101688] [Reference Citation Analysis]
16 Wood-Trageser MA, Lesniak AJ, Demetris AJ. Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring. Transplantation 2019;103:1306-22. [PMID: 30768568 DOI: 10.1097/TP.0000000000002656] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
17 Kim JM, Ryu JH, Lee KW, Hong SK, Yang K, Choi GS, Kim YA, Lee JY, Yi NJ, Kwon CHD, Chu CW, Suh KS, Joh JW. Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients. J Clin Med 2020;9:E2897. [PMID: 32911703 DOI: 10.3390/jcm9092897] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Choudhary NS, Saigal S, Gautam D, Saraf N, Soin AS. De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation: A Series of 4 Cases. J Clin Exp Hepatol 2018;8:314-7. [PMID: 30302049 DOI: 10.1016/j.jceh.2018.02.004] [Reference Citation Analysis]
19 Duizendstra AA, Doukas M, Betjes MGH, van den Bosch TPP, Darwish Murad S, Litjens NHR, Sprengers D, Kwekkeboom J. HLA matching and rabbit antithymocyte globulin as induction therapy to avoid multiple forms of rejection after a third liver transplantation. Clin Res Hepatol Gastroenterol 2021;45:101539. [PMID: 33109483 DOI: 10.1016/j.clinre.2020.08.014] [Reference Citation Analysis]
20 Valencia Deray KG, Hosek KE, Chilukuri D, Dunson JR, Spielberg DR, Swartz SJ, Spinner JA, Leung DH, Moulton EA, Munoz FM, Demmler-Harrison GJ, Bocchini CE. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant 2021. [PMID: 34467658 DOI: 10.1111/ajt.16822] [Reference Citation Analysis]
21 Demetris AJ. Longterm outcome of the liver graft: The pathologist's perspective. Liver Transpl 2017;23:S70-5. [DOI: 10.1002/lt.24851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
22 Martínez-Bravo MJ, Sánchez B, Sousa JM, Acevedo MJ, Gómez-Bravo MA, Núñez-Roldán A, Aguilera I. T-cell allorecognition of donor glutathione S-transferase T1 in plasma cell-rich rejection. World J Hepatol 2017; 9(27): 1115-1124 [PMID: 29026463 DOI: 10.4254/wjh.v9.i27.1115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Aguado-Domínguez E, Gómez L, Sousa JM, Gómez-Bravo MÁ, Núñez-Roldán A, Aguilera I. Identification of the cellular components involved in de novo immune hepatitis: a quantitative immunohistochemical analysis. J Transl Med 2018;16:62. [PMID: 29534755 DOI: 10.1186/s12967-018-1440-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Saunders EA, Engel B, Höfer A, Hartleben B, Vondran FWR, Richter N, Potthoff A, Zender S, Wedemeyer H, Jaeckel E, Taubert R. Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. Am J Transplant 2021. [PMID: 34455702 DOI: 10.1111/ajt.16817] [Reference Citation Analysis]
25 Adeyi OA. Pathology primer: Common liver biopsy findings in patients who have recently undergone liver transplant or resection. Clin Liver Dis (Hoboken) 2017;10:42-8. [PMID: 30992758 DOI: 10.1002/cld.652] [Reference Citation Analysis]
26 Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, Duong Van Huyen J, Taupin J, Glotz D, Legendre C, Loupy A, Halloran PF, Dragun D. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney International 2019;96:189-201. [DOI: 10.1016/j.kint.2019.01.030] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 27.5] [Reference Citation Analysis]
27 Madill-Thomsen K, Abouljoud M, Bhati C, Ciszek M, Durlik M, Feng S, Foroncewicz B, Francis I, Grąt M, Jurczyk K, Klintmalm G, Krasnodębski M, McCaughan G, Miquel R, Montano-Loza A, Moonka D, Mucha K, Myślak M, Pączek L, Perkowska-Ptasińska A, Piecha G, Reichman T, Sanchez-Fueyo A, Tronina O, Wawrzynowicz-Syczewska M, Więcek A, Zieniewicz K, Halloran PF. The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study. Am J Transplant 2020;20:2156-72. [PMID: 32090446 DOI: 10.1111/ajt.15828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
28 Vionnet J, Sempoux C, Pascual M, Sánchez-fueyo A, Colmenero J. Donor-specific antibodies in liver transplantation. Gastroenterología y Hepatología 2020;43:34-45. [DOI: 10.1016/j.gastrohep.2019.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
29 Hann A, Osei-Bordom DC, Neil DAH, Ronca V, Warner S, Perera MTPR. The Human Immune Response to Cadaveric and Living Donor Liver Allografts. Front Immunol 2020;11:1227. [PMID: 32655558 DOI: 10.3389/fimmu.2020.01227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Irie R, Nakazawa A, Sakamoto S, Takeda M, Yanagi Y, Shimizu S, Uchida H, Fukuda A, Miyazaki O, Nosaka S, Kasahara M. Living donor liver transplantation for congenital hepatic fibrosis in children. Pathol Int 2020;70:348-54. [PMID: 32118333 DOI: 10.1111/pin.12917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M, Fung J, Ghabril M, Thomason R, Burra P, Little EC, Berenguer M, Shaked A, Trotter J, Roberts J, Rodriguez-Davalos M, Rela M, Pomfret E, Heyrend C, Gallegos-Orozco J, Saliba F. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation 2018;102:727-43. [PMID: 29485508 DOI: 10.1097/TP.0000000000002147] [Cited by in Crossref: 61] [Cited by in F6Publishing: 22] [Article Influence: 30.5] [Reference Citation Analysis]
32 Berglund E, Andersen Ljungdahl M, Bogdanović D, Berglund D, Wadström J, Kowalski J, Brandacher G, Kamińska D, Kaufman CL, Talbot SG, Azari K, Landin L, Höhnke C, Dwyer KM, Cavadas PC, Thione A, Clarke B, Kay S, Wilks D, Iyer S, Iglesias M, Özkan Ö, Özkan Ö, Krapf J, Weissenbacher A, Petruzzo P, Schneeberger S. Clinical Significance of Alloantibodies in Hand Transplantation: A Multicenter Study. Transplantation 2019;103:2173-82. [DOI: 10.1097/tp.0000000000002650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
33 Toshida K, Toshima T, Yoshizumi T, Harada N, Itoh S, Nagao Y, Wang H, Shimagaki T, Kurihara T, Mori M. Immunosuppression Free Protocol for Liver Transplant from an Identical Twin Mimicking Positive Donor-Specific Antibodies: A Case Report. Transplant Proc 2021:S0041-1345(21)00255-4. [PMID: 34001347 DOI: 10.1016/j.transproceed.2021.04.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Höfer A, Jonigk D, Hartleben B, Verboom M, Hallensleben M, Hübscher SG, Manns MP, Jaeckel E, Taubert R. DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection. Transplantation 2020;104:551-61. [PMID: 31651790 DOI: 10.1097/TP.0000000000003034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
35 Krenzien F, Keshi E, Splith K, Griesel S, Kamali K, Sauer IM, Feldbrügge L, Pratschke J, Leder A, Schmelzle M. Diagnostic Biomarkers to Diagnose Acute Allograft Rejection After Liver Transplantation: Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies. Front Immunol 2019;10:758. [PMID: 31031758 DOI: 10.3389/fimmu.2019.00758] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
36 Pangonis S, Paulsen G, Andersen H, Flores F, Miethke A, Peters A, Kocoshis S, Lazear D, Garr B, Schecter M, Chin C, Hemmelgarn T, Danziger-Isakov L. Evaluation of a change in cytomegalovirus prevention strategy following pediatric solid organ transplantation. Transpl Infect Dis 2020;22:e13232. [PMID: 31840369 DOI: 10.1111/tid.13232] [Reference Citation Analysis]
37 Kerkar N, Vergani D. De novo autoimmune hepatitis –is this different in adults compared to children? Journal of Autoimmunity 2018;95:26-33. [DOI: 10.1016/j.jaut.2018.10.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
38 Dumortier J, Besch C, Moga L, Coilly A, Conti F, Corpechot C, Bello AD, Faitot F, Francoz C, Hilleret MN, Houssel-Debry P, Jezequel C, Lavayssière L, Neau-Cransac M, Erard-Poinsot D, de Lédinghen V, Bourlière M, Bureau C, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION. Clin Res Hepatol Gastroenterol 2021;:101774. [PMID: 34332131 DOI: 10.1016/j.clinre.2021.101774] [Reference Citation Analysis]
39 Feng S, Bucuvalas JC, Mazariegos GV, Magee JC, Sanchez-Fueyo A, Spain KM, Lesniak A, Kanaparthi S, Perito E, Venkat VL, Burrell BE, Alonso EM, Bridges ND, Doo E, Gupta NA, Himes RW, Ikle D, Jackson AM, Lobritto SJ, Jose Lozano J, Martinez M, Ng VL, Rand EB, Sherker AH, Sundaram SS, Turmelle YP, Wood-Trageser M, Demetris AJ. Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management. Hepatology 2021;73:1985-2004. [PMID: 32786149 DOI: 10.1002/hep.31520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
40 Ronca V, Wootton G, Milani C, Cain O. The Immunological Basis of Liver Allograft Rejection. Front Immunol 2020;11:2155. [PMID: 32983177 DOI: 10.3389/fimmu.2020.02155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
41 Roepe IG, Vierling JM, Goss JA, Miloh T. Presentation and Outcomes of Autoimmune Hepatitis Type 1 and Type 2 in Children: A Single-center Study. J Pediatr Gastroenterol Nutr 2021;72:101-7. [PMID: 32796427 DOI: 10.1097/MPG.0000000000002892] [Reference Citation Analysis]
42 Ueda D, Yoshizawa A, Kaneshiro M, Hirata Y, Yagi S, Hata K, Okajima H, Egawa H, Uemoto S. Low Titers of Antidonor ABO Antibodies After ABO-Incompatible Living Donor Liver Transplantation: A Long-Term Follow-Up Study. Transplant Direct 2019;5:e420. [PMID: 30656218 DOI: 10.1097/TXD.0000000000000858] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Cannon RM, Goldberg DS, Eckhoff DE, Anderson DJ, Orandi BJ, Locke JE. Early Outcomes With the Liver-kidney Safety Net. Transplantation 2021;105:1261-72. [PMID: 33741848 DOI: 10.1097/TP.0000000000003365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Couchonnal E, Rivet C, Ducreux S, Dumortier J, Bosch A, Boillot O, Collardeau-Frachon S, Dubois R, Hervieu V, André P, Scoazec JY, Lachaux A, Dubois V, Guillaud O. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. Transpl Immunol 2017;45:8-14. [PMID: 28782692 DOI: 10.1016/j.trim.2017.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
45 Chen GH, Wang GB, Huang F, Qin R, Yu XJ, Wu RL, Hou LJ, Ye ZH, Zhang XH, Zhao HC. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol. 2021;66:101386. [PMID: 33744409 DOI: 10.1016/j.trim.2021.101386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Katano T, Sanada Y, Hirata Y, Yamada N, Okada N, Onishi Y, Matsumoto K, Mizuta K, Sakuma Y, Sata N. Endovascular stent placement for venous complications following pediatric liver transplantation: outcomes and indications. Pediatr Surg Int 2019;35:1185-95. [PMID: 31535198 DOI: 10.1007/s00383-019-04551-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
47 Iesari S, Ackenine K, Foguenne M, De Reyck C, Komuta M, Bonaccorsi Riani E, Ciccarelli O, Coubeau L, Lai Q, Gianello P, Lerut J. Tacrolimus and Single Intraoperative High-dose of Anti-T-lymphocyte Globulins Versus Tacrolimus Monotherapy in Adult Liver Transplantation: One-year Results of an Investigator-driven Randomized Controlled Trial. Annals of Surgery 2018;268:776-83. [DOI: 10.1097/sla.0000000000002943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Tajima T, Hata K, Okajima H, Nishikori M, Yasuchika K, Kusakabe J, Yoshizawa A, Fukumitsu K, Anazawa T, Tanaka H, Wada S, Doi J, Takaori-Kondo A, Uemoto S. Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase? Transplant Direct 2019;5:e491. [PMID: 31723586 DOI: 10.1097/TXD.0000000000000932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
49 Dao M, Habès D, Taupin JL, Mussini C, Redon MJ, Suberbielle C, Jacquemin E, Gonzales E, Guettier C. Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients. Liver Transpl 2018;24:897-907. [PMID: 29704327 DOI: 10.1002/lt.25187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
50 Chae MS, Lee N, Choi HJ, Chung HS, Park CS, Lee J, Choi JH, Hong SH. Comparison of Liver Graft Regeneration Between ABO-Compatible and ABO-Incompatible Living Donor Liver Transplantation: A Propensity Score Matching Analysis. Ann Transplant 2018;23:507-19. [PMID: 30050031 DOI: 10.12659/AOT.908787] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Aguilera V, Di Maira T, Conde I, Fornés-Ferrer V, Vinaixa C, Pallarés C, Carvalho-Gomes A, Cubells A, García M, Rubín Á, Benlloch S, Gonzalez-Dieguez L, Molina JM, Puchades L, López-Labrador FX, Prieto M, Berenguer M. Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. Transpl Int 2018;31:649-57. [PMID: 29493818 DOI: 10.1111/tri.13145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Hong SK, Yi NJ, Hong K, Han ES, Lee JM, Choi Y, Lee KW, Suh KS. Risk Factors Affecting Outcomes in Pediatric Liver Transplantation: A Real-World Single-Center Experience. Ann Transplant 2021;26:e929145. [PMID: 34045429 DOI: 10.12659/AOT.929145] [Reference Citation Analysis]
53 Schotters FL, Beime J, Briem-Richter A, Binder T, Herden U, Grabhorn EF. Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation. World J Hepatol 2021; 13(6): 673-685 [PMID: 34239702 DOI: 10.4254/wjh.v13.i6.673] [Reference Citation Analysis]
54 Gül-Klein S, Hegermann H, Röhle R, Schmelzle M, Tacke F, Schöning W, Öllinger R, Dziodzio T, Maier P, Plewe JM, Horst D, Sauer IM, Pratschke J, Lachmann N, Eurich D. Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies. J Inflamm Res 2021;14:2697-712. [PMID: 34188517 DOI: 10.2147/JIR.S307778] [Reference Citation Analysis]
55 Dhanasekaran R. Management of Immunosuppression in Liver Transplantation. Clinics in Liver Disease 2017;21:337-53. [DOI: 10.1016/j.cld.2016.12.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
56 Ekong UD, McKiernan P, Martinez M, Lobritto S, Kelly D, Ng VL, Alonso EM, Avitzur Y. Long-term outcomes of de novo autoimmune hepatitis in pediatric liver transplant recipients. Pediatr Transplant. 2017;21. [PMID: 28556542 DOI: 10.1111/petr.12945] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
57 Lenggenhager D, Pawel S, Honcharova-Biletska H, Evert K, Wenzel JJ, Montani M, Furrer E, Fraga M, Moradpour D, Sempoux C, Weber A. The histologic presentation of hepatitis E reflects patients' immune status and pre-existing liver condition. Mod Pathol 2021;34:233-48. [PMID: 32572157 DOI: 10.1038/s41379-020-0593-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Kerkar N, Mayo MJ. Autoimmune Hepatitis: Highlights for Liver Transplant Providers From the American Association for the Study of Liver Diseases 2019 Guidelines. Liver Transpl 2020;26:973-6. [PMID: 32133751 DOI: 10.1002/lt.25740] [Reference Citation Analysis]
59 Wakabayashi T, Shinoda M, Obara H, Kitago M, Yagi H, Abe Y, Matsubara K, Yamada Y, Oshima G, Hirukawa K, Mizota T, Hibi T, Itano O, Hoshino K, Kuroda T, Kitagawa Y. Decreased Incidence of Acute Cellular Rejection in Low-Muscle-Mass Recipients After Living-donor Liver Transplantation. Transplantation Proceedings 2018;50:3626-34. [DOI: 10.1016/j.transproceed.2018.06.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Berger M, Lefaucheur C, Jordan SC. Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation. Transplantation 2019;103:1763-75. [PMID: 30946220 DOI: 10.1097/TP.0000000000002717] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 15.0] [Reference Citation Analysis]
61 Rock NM, Anghileri E, Cousin VL, Petit LM, McLin VA. Vitamin D Insufficiency Prior to Paediatric Liver Transplantation Is Associated with Early T-Cell Mediated Rejection. Children (Basel) 2021;8:612. [PMID: 34356591 DOI: 10.3390/children8070612] [Reference Citation Analysis]
62 Hong SK, Han D, Lee SK, Kim J, Hwang ES, Kim H, Lee JI, Hong K, Han ES, Cho JH, Lee JM, Choi Y, Lee KW, Yi NJ, Yang J, Suh KS. Short-term therapy with anti-ICAM-1 monoclonal antibody induced long-term liver allograft survival in nonhuman primates. Am J Transplant 2021;21:2978-91. [PMID: 33423374 DOI: 10.1111/ajt.16486] [Reference Citation Analysis]
63 Kelly D, Verkade HJ, Rajanayagam J, Mckiernan P, Mazariegos G, Hübscher S. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: Current concepts and future developments. Liver Transpl 2016;22:1593-602. [DOI: 10.1002/lt.24616] [Cited by in Crossref: 69] [Cited by in F6Publishing: 46] [Article Influence: 13.8] [Reference Citation Analysis]
64 Cousin VL, Rougemont AL, Rubbia-Brandt L, Wildhaber BE, Villard J, Ferrari-Lacraz S, McLin VA. Peripheral Donor-specific Antibodies Are Associated With Histology and Cellular Subtypes in Protocol Liver Biopsies of Pediatric Recipients. Transplantation 2020;104:1633-43. [PMID: 32732841 DOI: 10.1097/TP.0000000000003099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
65 Friman S, Tisone G, Nevens F, Lehner F, Santaniello W, Bechstein WO, Zhuvarel SV, Isoniemi H, Rummo OO, Klempnauer J, Anaokar S, Hurst M, Kazeem G, Undre N, Trunečka P. Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study. Transplant Direct 2021;7:e722. [PMID: 34263020 DOI: 10.1097/TXD.0000000000001166] [Reference Citation Analysis]
66 O'leary JG, Demetris AJ, Philippe A, Freeman R, Cai J, Heidecke H, Smith C, Hart B, Jennings LW, Catar R, Everly M, Klintmalm GB, Dragun D. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation 2017;101:2399-409. [DOI: 10.1097/tp.0000000000001853] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
67 Courbage S, Canioni D, Talbotec C, Lambe C, Chardot C, Rabant M, Galmiche L, Corcos O, Goulet O, Joly F, Lacaille F. Beyond 10 years, with or without an intestinal graft: Present and future? Am J Transplant 2020;20:2802-12. [PMID: 32277553 DOI: 10.1111/ajt.15899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
68 Kovandova B, Slavcev A, Sekerkova Z, Honsova E, Trunecka P. Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies. HLA 2018;92:34-7. [DOI: 10.1111/tan.13354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
69 Skogsberg Dahlgren U, Herlenius G, Gustafsson B, Mölne J, Rydberg L, Socratous A, Bennet W. Excellent outcome following emergency deceased donor ABO-incompatible liver transplantation using rituximab and antigen specific immunoadsorption. Scand J Gastroenterol 2021;:1-10. [PMID: 34541993 DOI: 10.1080/00365521.2021.1976269] [Reference Citation Analysis]
70 Kohut TJ, Barandiaran JF, Keating BJ. Genomics and Liver Transplantation: Genomic Biomarkers for the Diagnosis of Acute Cellular Rejection. Liver Transpl 2020;26:1337-50. [DOI: 10.1002/lt.25812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Jang JK, Kim KW, Choi SH, Jeong SY, Kim JH, Yu ES, Kwon JH, Song GW, Lee SG. CT of acute rejection after liver transplantation: a matched case-control study. Eur Radiol 2019;29:3736-45. [PMID: 30707276 DOI: 10.1007/s00330-018-5971-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Biewenga M, Farina Sarasqueta A, Tushuizen ME, de Jonge-Muller ESM, van Hoek B, Trouw LA. The role of complement activation in autoimmune liver disease. Autoimmun Rev 2020;19:102534. [PMID: 32234403 DOI: 10.1016/j.autrev.2020.102534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
73 Del Bello A, Neau‐cransac M, Lavayssiere L, Dubois V, Congy‐jolivet N, Visentin J, Danjoux M, Le Bail B, Hervieu V, Boillot O, Antonini T, Kamar N, Dumortier J. Outcome of Liver Transplant Patients With Preformed Donor‐Specific Anti–Human Leukocyte Antigen Antibodies. Liver Transpl 2019;26:256-67. [DOI: 10.1002/lt.25663] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
74 Mazariegos GV, Shneider BL, Shemesh E, Schady D, Melin-Aldana H, Cho SJ, Anand R, Erinjeri J, Annunziato R, Reyes-Mugica M. Approaches to Research Determination of Late Acute Cellular Rejection in Pediatric Liver Transplant Recipients. Liver Transpl 2021;27:106-15. [PMID: 32978871 DOI: 10.1002/lt.25903] [Reference Citation Analysis]
75 Thorgersen EB, Barratt-Due A, Haugaa H, Harboe M, Pischke SE, Nilsson PH, Mollnes TE. The Role of Complement in Liver Injury, Regeneration, and Transplantation. Hepatology. 2019;70:725-736. [PMID: 30653682 DOI: 10.1002/hep.30508] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 19.0] [Reference Citation Analysis]
76 González I, Lu H, Ritter JH, Maluf HM, Dehner LP, He M. Clinicopathologic characteristics of de novo nodular regenerative hyperplasia in pediatric liver transplant. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Bruneval P, Angelini A, Miller D, Potena L, Loupy A, Zeevi A, Reed EF, Dragun D, Reinsmoen N, Smith RN, West L, Tebutt S, Thum T, Haas M, Mengel M, Revelo P, Fedrigo M, Duong Van Huyen JP, Berry GJ. The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. Am J Transplant 2017;17:42-53. [PMID: 27862968 DOI: 10.1111/ajt.14112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
78 Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, Poinsot D, André P, Scoazec JY, Robinson P, Boillot O, Dubois V, Dumortier J. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation. Liver Transpl 2018;24:1091-100. [PMID: 29665189 DOI: 10.1002/lt.25177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
79 Sultani B, Marget M, Briem-Richter A, Herrmann J, Meisner S, Grabhorn EF, Ozga AK, Weidemann S, Herden U, Fischer L, Sterneck M. Presence of donor specific HLA class 2 antibodies (DSA class 2) is associated with development of graft fibrosis more than 10 years after liver transplantation-a retrospective single center study. Clin Transplant 2021;35:e14336. [PMID: 33949011 DOI: 10.1111/ctr.14336] [Reference Citation Analysis]
80 Navez J, Iesari S, Kourta D, Baami-Mariza K, Nadiri M, Goffette P, Baldin P, Ackenine K, Bonaccorsi-Riani E, Ciccarelli O, Coubeau L, Moreels T, Lerut J. The real incidence of biliary tract complications after adult liver transplantation: the role of the prospective routine use of cholangiography during post-transplant follow-up. Transpl Int 2021;34:245-58. [PMID: 33188645 DOI: 10.1111/tri.13786] [Reference Citation Analysis]
81 Millán O, Ruiz P, Fortuna V, Navasa M, Brunet M. Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients. Liver Int 2020;40:931-46. [PMID: 31883422 DOI: 10.1111/liv.14339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
82 Del Bello A, Danjoux M, Congy-jolivet N, Lavayssière L, Esposito L, Muscari F, Kamar N. Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation: Outcome of antibody mediated rejection. Journal of Gastroenterology and Hepatology 2017;32:887-93. [DOI: 10.1111/jgh.13613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
83 Hassan S, Ng VL, Aqul A. It takes a village: primary care of the pediatric liver transplant recipient. Curr Opin Pediatr 2019;31:636-44. [PMID: 31369476 DOI: 10.1097/MOP.0000000000000809] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Moris D, Cendales LC. Sensitization and Desensitization in Vascularized Composite Allotransplantation. Front Immunol 2021;12:682180. [PMID: 34456906 DOI: 10.3389/fimmu.2021.682180] [Reference Citation Analysis]
85 Akamatsu N, Hasegawa K, Sakamoto S, Ohdan H, Nakagawa K, Egawa H. Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey. Transplant Direct 2021;7:e729. [PMID: 34291151 DOI: 10.1097/TXD.0000000000001180] [Reference Citation Analysis]
86 Angelico R, Gerlach UA, Gunson BK, Neil D, Mergental H, Isaac J, Muiesan P, Mirza D, Perera MTP. Severe Unresolved Cholestasis Due to Unknown Etiology Leading to Early Allograft Failure Within the First 3 Months of Liver Transplantation. Transplantation 2018;102:1307-15. [DOI: 10.1097/tp.0000000000002139] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
87 Schluckebier D, Cousin VL, Petit L, Belli D, Wildhaber B, Rougemont A, Villard J, Ferrari‐lacraz S, Mclin VA. Preformed and de novo DSA are associated with T‐cell–mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy. Pediatr Transplant 2020;24. [DOI: 10.1111/petr.13611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Hammond MEH, Kfoury AG. Antibody-mediated rejection in the cardiac allograft: diagnosis, treatment and future considerations. Curr Opin Cardiol 2017;32:326-35. [PMID: 28212151 DOI: 10.1097/HCO.0000000000000390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
89 Schiano TD, Florman S, Fiel MI. Recurrent Idiopathic Liver Allograft Failure. Am J Clin Pathol 2019;152:369-76. [PMID: 31139817 DOI: 10.1093/ajcp/aqz044] [Reference Citation Analysis]
90 Moon A, Smith GH, Kong J, Rogers TE, Ellis CL, Farris AB“. Development of CD3 cell quantitation algorithms for renal allograft biopsy rejection assessment utilizing open source image analysis software. Virchows Arch 2018;472:259-69. [DOI: 10.1007/s00428-017-2260-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
91 Beyzaei Z, Geramizadeh B, Bagheri Z, Karimzadeh S, Shojazadeh A. De Novo Donor Specific Antibody and Long-Term Outcome After Liver Transplantation: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:613128. [PMID: 33424868 DOI: 10.3389/fimmu.2020.613128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Aguilera I, Aguado-Dominguez E, Sousa JM, Nuñez-Roldan A. Rethinking de novo immune hepatitis, an old concept for liver allograft rejection: Relevance of glutathione S-transferase T1 mismatch. World J Gastroenterol 2018; 24(29): 3239-3249 [PMID: 30090004 DOI: 10.3748/wjg.v24.i29.3239] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
93 Irie R, Nakazawa A, Sakamoto S, Takeda M, Yanagi Y, Shimizu S, Uchida H, Fukuda A, Horikawa R, Kasahara M. Etiology of liver dysfunction after liver transplantation in children with metabolic disorders. Hepatol Res 2020;50:635-42. [PMID: 31957215 DOI: 10.1111/hepr.13487] [Reference Citation Analysis]
94 Tamura K, Tohyama T, Watanabe J, Nakamura T, Ueno Y, Inoue H, Honjo M, Sakamoto K, Takai A, Ogawa K, Takada Y. Preformed donor-specific antibodies are associated with 90-day mortality in living-donor liver transplantation. Hepatol Res 2019;49:929-41. [PMID: 30991451 DOI: 10.1111/hepr.13352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Baliellas C, Lladó L, Serrano T, Gonzalez-Vilatarsana E, Cachero A, Lopez-Dominguez J, Petit A, Fabregat J. Sinusoidal obstruction syndrome as a manifestation of acute antibody-mediated rejection after liver transplantation. Am J Transplant 2021. [PMID: 34008326 DOI: 10.1111/ajt.16689] [Reference Citation Analysis]
96 Angelico R, Spada M, Liccardo D, Pedini D, Grimaldi C, Pietrobattista A, Basso MS, Della Corte C, Mosca A, Saffioti MC, Alaggio R, Maggiore G, Candusso M, Francalanci P. Allograft Fibrosis After Pediatric Liver Transplantation: Incidence, Risk Factors, and Evolution. Liver Transpl 2021. [PMID: 34164907 DOI: 10.1002/lt.26218] [Reference Citation Analysis]
97 Kovandova B, Slavcev A, Honsova E, Erhartova D, Skibova J, Viklicky O, Trunecka P. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study. Transpl Int 2020;33:1799-806. [PMID: 33020979 DOI: 10.1111/tri.13763] [Reference Citation Analysis]
98 Guiral S, Segundo DS, Irure J, Casafont F, Fortea JI, Puente Á, López-hoyos M, Crespo J, Fabrega E. Number of Antibody-verified Eplet in HLA-C Locus as an Independent Factor of T-cell–Mediated Rejection After Liver Transplantation. Transplantation 2020;104:562-7. [DOI: 10.1097/tp.0000000000002921] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
99 Londoño MC, Souza LN, Lozano JJ, Miquel R, Abraldes JG, Llovet LP, Quaglia A, Rimola A, Navasa M, Sánchez-Fueyo A. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. J Hepatol 2018;69:626-34. [PMID: 29709679 DOI: 10.1016/j.jhep.2018.04.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
100 Darstein F, Häuser F, Straub BK, Wenzel JJ, Conradi R, Mittler J, Lang H, Galle PR, Zimmermann T. Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real-world cohort: XXXX. Clin Transplant 2018;32:e13411. [DOI: 10.1111/ctr.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Ma L, Li M, Zhang T, Xu JQ, Cao XB, Wu SS, Sun LY. Incidence of de novo autoimmune hepatitis in children and adolescents with increased autoantibodies after liver transplantation: a meta-analysis. Transpl Int 2021;34:412-22. [PMID: 33316839 DOI: 10.1111/tri.13801] [Reference Citation Analysis]
102 Chhabra M, Alsughayyir J, Qureshi MS, Mallik M, Ali JM, Gamper I, Moseley EL, Peacock S, Kosmoliaptsis V, Goddard MJ, Linterman MA, Motallebzadeh R, Pettigrew GJ. Germinal Center Alloantibody Responses Mediate Progression of Chronic Allograft Injury. Front Immunol 2018;9:3038. [PMID: 30728823 DOI: 10.3389/fimmu.2018.03038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
103 Papachristou M, Fylaktou A, Daoudaki M, Cholongitas E, Karampatakis T, Anastasiou A, Chatzika G, Makrovasili F, Vagiotas L, Karakasi K, Fouzas I. Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation. Transplant Proc 2019;51:424-8. [PMID: 30879557 DOI: 10.1016/j.transproceed.2019.01.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
104 Ibáñez-samaniego L, Salcedo M, Vaquero J, Bañares R. De novo autoimmune hepatitis after liver transplantation: A focus on glutathione S-transferase theta 1: ibáñez-Samaniego et al. Liver Transpl 2017;23:75-85. [DOI: 10.1002/lt.24652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
105 Feng S, Bucuvalas JC, Demetris AJ, Burrell BE, Spain KM, Kanaparthi S, Magee JC, Ikle D, Lesniak A, Lozano JJ, Alonso EM, Bray RA, Bridges NE, Doo E, Gebel HM, Gupta NA, Himes RW, Jackson AM, Lobritto SJ, Mazariegos GV, Ng VL, Rand EB, Sherker AH, Sundaram S, Turmelle YP, Sanchez-Fueyo A. Evidence of Chronic Allograft Injury in Liver Biopsies From Long-term Pediatric Recipients of Liver Transplants. Gastroenterology 2018;155:1838-1851.e7. [PMID: 30144432 DOI: 10.1053/j.gastro.2018.08.023] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 19.0] [Reference Citation Analysis]
106 Markiewicz-Kijewska M, Kaliciński P, Torres Canizales J, Di Giorgio A, Baumann U, Jorns C, Baker A, Lopes MF, Frauca Remacha E, Lopez-Granados E, Jara Vega P, Basso MS, Kowalewski G, Kamińska D, Ferreira S, Liccardo D, Pietrobattista A, Spada M, On Behalf Of Ern TransplantChild Healthcare Working Group. ABO Incompatible Liver Transplantation in Children: A 20 Year Experience from Centres in the TransplantChild European Reference Network. Children (Basel) 2021;8:760. [PMID: 34572193 DOI: 10.3390/children8090760] [Reference Citation Analysis]
107 Nakamura T, Shirouzu T, Kawai S, Matsuyama T, Harada S, Nobori S, Yoshimura N, Ushigome H. Graft Immunocomplex Capture Fluorescence Analysis Can Detect Intragraft Anti-Major Histocompatibility Complex Antibodies in Mice Cardiac Transplant. Transplant Proc 2019;51:1531-5. [PMID: 31053346 DOI: 10.1016/j.transproceed.2019.01.114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Davidovich E, Mozer Y, Polak D. Salivary inflammatory cytokines echo the low inflammatory burden in liver-transplanted children. Clin Oral Investig 2021;25:2993-8. [PMID: 33140161 DOI: 10.1007/s00784-020-03619-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S, Menon K, Mirza D, Neuberger J, Prasad R, Pratt A, Prentice W, Shepherd L, Simpson K, Thorburn D, Westbrook R, Tripathi D. Adult liver transplantation: UK clinical guideline - part 2: surgery and post-operation. Frontline Gastroenterol 2020;11:385-96. [PMID: 32879722 DOI: 10.1136/flgastro-2019-101216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
110 Booth IA, Clark JE, LaMattina JC, Barth RN, Haririan A, Ravichandran BR. The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes. J Pharm Pract 2021;:8971900211034261. [PMID: 34289722 DOI: 10.1177/08971900211034261] [Reference Citation Analysis]
111 Sheikh A, Chau KY, Evans HM. Histological findings in protocol biopsies following pediatric liver transplant: Low incidence of abnormalities at 5 years. Pediatr Transplant. 2018;22:e13212. [PMID: 29749699 DOI: 10.1111/petr.13212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
112 Thomson AW, Humar A, Lakkis FG, Metes DM. Regulatory dendritic cells for promotion of liver transplant operational tolerance: Rationale for a clinical trial and accompanying mechanistic studies. Hum Immunol 2018;79:314-21. [PMID: 29100944 DOI: 10.1016/j.humimm.2017.10.017] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
113 Stevenson HL, Prats MM, Isse K, Zeevi A, Avitzur Y, Ng VL, Demetris AJ. Isolated vascular “v” lesions in liver allografts: How to approach this unusual finding. Am J Transplant 2018;18:1534-43. [DOI: 10.1111/ajt.14708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
114 Shimizu S, Sakamoto S, Yamada M, Fukuda A, Yanagi Y, Uchida H, Mimori K, Shoji K, Funaki T, Miyairi I, Nakano N, Haga C, Yoshioka T, Imadome KI, Horikawa R, Kasahara M. Immunological features and complications in patients with glycogen storage disease 1b after living donor liver transplantation. Pediatr Transplant 2021;:e14104. [PMID: 34339091 DOI: 10.1111/petr.14104] [Reference Citation Analysis]
115 Hann A, Oo YH, Perera MTPR. Regulatory T-Cell Therapy in Liver Transplantation and Chronic Liver Disease. Front Immunol 2021;12:719954. [PMID: 34721383 DOI: 10.3389/fimmu.2021.719954] [Reference Citation Analysis]
116 Cvetkovski F, Hexham JM, Berglund E. Strategies for Liver Transplantation Tolerance. Int J Mol Sci 2021;22:2253. [PMID: 33668238 DOI: 10.3390/ijms22052253] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
118 Stirnimann G, Ebadi M, Czaja AJ, Montano‐loza AJ. Recurrent and De Novo Autoimmune Hepatitis. Liver Transpl 2019;25:152-66. [DOI: 10.1002/lt.25375] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 14.5] [Reference Citation Analysis]
119 Yamada Y, Hoshino K, Mori T, Kawaida M, Abe K, Ishihama H, Shimizu T, Takahashi N, Matsubara K, Hibi T, Abe Y, Yagi H, Shimojima N, Shinoda M, Kitago M, Obara H, Fuchimoto Y, Kameyama K, Kitagawa Y, Kuroda T. Successful living donor liver retransplantation for graft failure within 7 days due to acute de novo donor-specific anti-human leukocyte antigen antibody-mediated rejection: Re-LTx for graft failure secondary to de novo AMR. Hepatol Res 2018;48:E360-6. [DOI: 10.1111/hepr.12924] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
120 Wozniak LJ, Naini BV, Hickey MJ, Bhattacharyya S, Reed EF, Busuttil RW, Farmer DG, Vargas JH, Venick RS, McDiarmid SV. Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature. Pediatr Transplant. 2017;21. [PMID: 27597379 DOI: 10.1111/petr.12791] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
121 Sakamoto S, Akamatsu N, Hasegawa K, Ohdan H, Nakagawa K, Egawa H. The efficacy of rituximab treatment for antibody-mediated rejection in liver transplantation: A retrospective Japanese nationwide study. Hepatol Res 2021;51:990-9. [PMID: 33818877 DOI: 10.1111/hepr.13643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
122 Newland DM, Royston MJ, Mcdonald DR, Nemeth TL, Wallace‐boughter K, Carlin K, Horslen S. Analysis of rabbit anti‐thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Smith K, Perito ER. Donor-Specific and Auto-Antibodies in Pediatric Liver Transplant: When Are They Important? What Do They Mean? J Pediatr Gastroenterol Nutr 2021;72:643-4. [PMID: 33720098 DOI: 10.1097/MPG.0000000000003093] [Reference Citation Analysis]
124 Lee M. Antibody-Mediated Rejection After Liver Transplant. Gastroenterology Clinics of North America 2017;46:297-309. [DOI: 10.1016/j.gtc.2017.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
125 Choi JK, Ahn S, Cho JY, Choi Y, Han HS, Jang BO, Choi GH, Jang ES, Kim JW, Jeong SH. A case of acute liver failure due to hepatitis E virus, liver transplantation, and development of de novo autoimmune hepatitis. Transpl Infect Dis 2020;22:e13287. [PMID: 32279435 DOI: 10.1111/tid.13287] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Chen L, Himmelfarb EA, Sun M, Choi EK, Fan L, Lai J, Kim CJ, Xu H, Wang HL. Immunostaining Patterns of Posttransplant Liver Biopsies Using 2 Anti-C4d Antibodies. Appl Immunohistochem Mol Morphol 2020;28:146-53. [PMID: 32044883 DOI: 10.1097/PAI.0000000000000723] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Arterbery AS, Yao J, Ling A, Avitzur Y, Martinez M, Lobritto S, Deng Y, Geliang G, Mehta S, Wang G, Knight J, Ekong UD. Inflammasome Priming Mediated via Toll-Like Receptors 2 and 4, Induces Th1-Like Regulatory T Cells in De Novo Autoimmune Hepatitis. Front Immunol 2018;9:1612. [PMID: 30072988 DOI: 10.3389/fimmu.2018.01612] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
128 Brown RM, Hübscher SG. Role of Histology Following Pediatric Liver Transplantation. Pediatric Liver Transplantation. Elsevier; 2021. pp. 223-32. [DOI: 10.1016/b978-0-323-63671-1.00024-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Decker SO, Hildebrand D, Bruckner T, Lichtenstern C, Heeg K, Weigand MA, Brenner T, Uhle F. Delta-like Canonical Notch Ligand 1 in Patients Following Liver Transplantation-A Secondary Analysis of a Prospective Cohort Study. Diagnostics (Basel) 2020;10:E894. [PMID: 33142943 DOI: 10.3390/diagnostics10110894] [Reference Citation Analysis]
130 Aguado-Dominguez E, Sousa JM, Perez-Simon JA, Aguilera I. Clinical association of anti-glutathione S-transferase T1 antibodies and de novo immune hepatitis after hematopoietic cell transplantation. Dig Liver Dis. 2018;50:418-419. [PMID: 29409781 DOI: 10.1016/j.dld.2017.12.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
131 Kim JM, Oh JW, Kim S, Rhu J, Lee JS, Kim KS, Choi GS, Joh JW. Tablet or capsule form of generic mycophenolate mofetil (My-Rept®) after liver transplantation: a prospective randomized trial. Drug Des Devel Ther 2019;13:2187-93. [PMID: 31308630 DOI: 10.2147/DDDT.S204056] [Reference Citation Analysis]
132 McCabe M, Rush N, Lammert C, Patidar KR, Nephew L, Saxena R, Ekser B, Salven J, Kubal C, Ghabril M. HLA-DR Mismatch and Black Race Are Associated With Recurrent Autoimmune Hepatitis After Liver Transplantation. Transplant Direct 2021;7:e714. [PMID: 34131586 DOI: 10.1097/TXD.0000000000001160] [Reference Citation Analysis]
133 Akamatsu N, Hasegawa K, Egawa H, Ohdan H, Yoshizawa A, Kokudo N, Tazuma S, Tanaka A, Takikawa H. Donor age (≥45 years) and reduced immunosuppression are associated with the recurrent primary sclerosing cholangitis after liver transplantation - a multicenter retrospective study. Transpl Int 2021;34:916-29. [PMID: 33629379 DOI: 10.1111/tri.13852] [Reference Citation Analysis]
134 Sousa JM, Barrera L, Gomez-Bravo MA, Nuñez-Roldan A, Aguilera I. Glutathione S-Transferase T1 Mismatch Is a Risk Factor for Chronic Ductopenic Rejection of Liver Allografts. Liver Transpl 2020;26:1287-97. [PMID: 32510757 DOI: 10.1002/lt.25815] [Reference Citation Analysis]
135 Liu L, Fang C, Fu W, Jiang B, Li G, Qin L, Rosenbluth J, Gong G, Xie CB, Yoo P, Tellides G, Pober JS, Jane-Wit D. Endothelial Cell-Derived Interleukin-18 Released During Ischemia Reperfusion Injury Selectively Expands T Peripheral Helper Cells to Promote Alloantibody Production. Circulation 2020;141:464-78. [PMID: 31744330 DOI: 10.1161/CIRCULATIONAHA.119.042501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
136 Chiou FK, Beath SV, Morland B, Hartley J, van Mourik I, Abdel-hady M, Kelly DA, Sharif K, Gupte GL. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation. Transplantation 2020;104:1429-36. [DOI: 10.1097/tp.0000000000003004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
137 Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther. 2017;45:485-500. [PMID: 27957759 DOI: 10.1111/apt.13894] [Cited by in Crossref: 57] [Cited by in F6Publishing: 39] [Article Influence: 11.4] [Reference Citation Analysis]
138 Del Bello A, Thaunat O, Le Quintrec M, Bestard O, Durrbach A, Perrin P, Gatault P, Jambon F, Pageaux GP, Llado L, Besch C, Barbier L, Neau-Cransac M, Dumortier J, Kamar N. Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. Kidney Int Rep 2020;5:2202-11. [PMID: 33305113 DOI: 10.1016/j.ekir.2020.09.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. Journal of Hepatology 2019;70:745-58. [DOI: 10.1016/j.jhep.2018.12.009] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 31.0] [Reference Citation Analysis]
140 Guerra MR, Naini BV, Scapa JV, Reed EF, Busuttil RW, Cheng EY, Farmer DG, Vargas JH, Venick RS, McDiarmid SV, Wozniak LJ. Obliterative portal venopathy: A histopathologic finding associated with chronic antibody-mediated rejection in pediatric liver allografts. Pediatr Transplant. 2018;22. [PMID: 29363222 DOI: 10.1111/petr.13124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
141 Wozniak LJ, Venick RS. Donor-specific antibodies following liver and intestinal transplantation: Clinical significance, pathogenesis and recommendations. International Reviews of Immunology 2019;38:106-17. [DOI: 10.1080/08830185.2019.1630404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
142 Levitsky J, Kandpal M, Guo K, Kleiboeker S, Sinha R, Abecassis M. Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients. Am J Transplant 2021. [PMID: 34510731 DOI: 10.1111/ajt.16835] [Reference Citation Analysis]
143 Appenzeller-Herzog C, Hartleif S, Vionnet J. Clinical parameters and biomarkers predicting spontaneous operational tolerance after liver transplantation: A scoping review. Am J Transplant 2021. [PMID: 33783969 DOI: 10.1111/ajt.16585] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Barreto SG, Brooke-Smith ME, Neo EL, Dolan P, Leibbrandt R, Emery T, Carroll R, Wigg A, Chen JW. Exploring pre-surgery donor-specific antibodies in the context of organ shortage in liver transplant. Langenbecks Arch Surg 2019;404:865-74. [PMID: 31748871 DOI: 10.1007/s00423-019-01831-9] [Reference Citation Analysis]
145 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 104.0] [Reference Citation Analysis]
146 O'Leary JG, Smith C, Cai J, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome. Transplantation 2017;101:2062-70. [PMID: 28452922 DOI: 10.1097/TP.0000000000001802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
147 González IA, Hartley CP, Nalbantoglu I. Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft. Am J Clin Pathol 2021;155:435-45. [PMID: 33252121 DOI: 10.1093/ajcp/aqaa147] [Reference Citation Analysis]
148 Mysore KR, Phan TL, Himes RW, Schady D, Eldin KW, Prusty BK, Munoz FM. Human Herpesvirus 6 Infection in Pediatric Liver Transplantation: Single-Center Study of Incidence, Outcomes, and Management. J Pediatric Infect Dis Soc 2021;10:599-606. [PMID: 33491073 DOI: 10.1093/jpids/piaa166] [Reference Citation Analysis]
149 Alswat K, Soliman E, Salih I, Bashmail A, Letierce A, Benmousa A, Alghamdi S, Bzeizi KI, Alqahtani SA, Shawkat M, Broering DC, Al-Hamoudi WK. Long Term Outcomes of Liver Transplantation For Patients With Autoimmune Hepatitis. Transplant Proc 2021;53:2339-45. [PMID: 34474912 DOI: 10.1016/j.transproceed.2021.07.040] [Reference Citation Analysis]
150 Butler CL, Valenzuela NM, Thomas KA, Reed EF. Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection. J Immunol Res 2017;2017:7903471. [PMID: 28373996 DOI: 10.1155/2017/7903471] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
151 O'grady J. Antibody-Mediated Injury to the Transplanted Liver: Receiving the Sages' Wisdom. Am J Transplant 2016;16:2773-4. [DOI: 10.1111/ajt.13954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
152 Egawa H, Umeshita K, Uemoto S. Optimal dosage regimen for rituximab in ABO-incompatible living donor liver transplantation. J Hepatobiliary Pancreat Sci. 2017;24:89-94. [PMID: 28002655 DOI: 10.1002/jhbp.419] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
153 Takeda M, Sakamoto S, Irie R, Uchida H, Shimizu S, Yanagi Y, Abdelwahed MS, Fukuda A, Kasahara M. Late T cell-mediated rejection may contribute to poor outcomes in adolescents and young adults with liver transplantation. Pediatr Transplant 2020;24:e13708. [PMID: 32333637 DOI: 10.1111/petr.13708] [Reference Citation Analysis]
154 Darstein F, Häuser F, Mittler J, Zimmermann A, Lautem A, Hoppe-Lotichius M, Otto G, Lang H, Galle PR, Zimmermann T. Hepatitis E Is a Rare Finding in Liver Transplant Patients With Chronic Elevated Liver Enzymes and Biopsy-Proven Acute Rejection. Transplant Proc 2020;52:926-31. [PMID: 32139278 DOI: 10.1016/j.transproceed.2020.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Matsuura T, Kohashi K, Kawano Y, Takahashi Y, Yoshimaru K, Yoshizumi T, Oda Y, Mori M, Taguchi T. Successful management to prevent early graft loss due to Seventh-day Syndrome after liver retransplantation: A case report and literature review. Pediatr Transplant 2021;25:e13907. [PMID: 33135813 DOI: 10.1111/petr.13907] [Reference Citation Analysis]
156 Zhang Y, Ye S, Liu D, He W, Zhong Z, Ye Q, Xiong Y. Assessment of Donor Liver Pathology Predicts Survival After Liver Transplantation: A Retrospective Cohort Study. Transplant Proc 2021:S0041-1345(21)00692-8. [PMID: 34736781 DOI: 10.1016/j.transproceed.2021.09.015] [Reference Citation Analysis]
157 Koo J, Wang HL. Acute, Chronic, and Humoral Rejection. Surgical Pathology Clinics 2018;11:431-52. [DOI: 10.1016/j.path.2018.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
158 Meszaros M, Niemann M, Ursic-Bedoya J, Faure S, Meunier L, Rivière B, Costes-Martineau V, Thevenin C, Pageaux GP. Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study. Transpl Immunol 2020;59:101272. [PMID: 32061667 DOI: 10.1016/j.trim.2020.101272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
159 Ünlü S, Lachmann N, Jara M, Ritschl PV, Wiering L, Eurich D, Denecke C, Biebl M, Chopra S, Gül-Klein S, Schöning W, Schmelzle M, Reinke P, Tacke F, Pratschke J, Öllinger R, Dziodzio T. Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation. J Clin Med 2020;9:E3986. [PMID: 33317012 DOI: 10.3390/jcm9123986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 González IA, Lu HC, Alipour Z, Kulkarni SS, Stoll JM, Liss KHH, Dehner LP, He M. Clinicopathologic Characteristics of Centrilobular Injury in Pediatric Liver Transplantation. Liver Transpl 2021;27:416-24. [PMID: 33253466 DOI: 10.1002/lt.25958] [Reference Citation Analysis]
161 Nakamura T, Shirouzu T, Nakata K, Yoshimura N, Ushigome H. The Role of Major Histocompatibility Complex in Organ Transplantation- Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage. Int J Mol Sci 2019;20:E4544. [PMID: 31540289 DOI: 10.3390/ijms20184544] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
162 Joher N, Matignon M, Grimbert P. HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers. Front Immunol 2021;12:688301. [PMID: 34093594 DOI: 10.3389/fimmu.2021.688301] [Reference Citation Analysis]
163 Baba HA, Theurer S, Canbay A, Schwertheim S, Lainka E, Kälsch J, Wohlschläger J. [Liver transplantation. Current aspects of pretransplantation diagnosis and rejection]. Pathologe 2020;41:505-14. [PMID: 32776226 DOI: 10.1007/s00292-020-00813-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Wesson RN, Etchill EW, Garonzik-Wang J. Application and interpretation of histocompatibility data in liver transplantation. Curr Opin Organ Transplant. 2017;22:499-504. [PMID: 28708813 DOI: 10.1097/mot.0000000000000450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
165 Cheng EY. The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives. J Immunol Res. 2017;2017:3234906. [PMID: 28164136 DOI: 10.1155/2017/3234906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
166 Rosso F, Sanz AM, Parra-Lara LG, Moncada PA, Vélez JD, Caicedo LA. Dengue Virus Infection in Solid Organ Transplant Recipients: A Case Series and Literature Review. Am J Trop Med Hyg 2019;101:1226-31. [PMID: 31628736 DOI: 10.4269/ajtmh.19-0414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Choi D, Liu M, Guttikonda D, Galen K, Guzman G, Jeon H, Aloman C. Recipient risk factors for acute cellular rejection after orthotopic liver transplant - a single-center, retrospective study. Transpl Int 2020;33:1779-87. [PMID: 32990344 DOI: 10.1111/tri.13756] [Reference Citation Analysis]
168 Lefaucheur C, Louis K, Philippe A, Loupy A, Coates PT. The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. Kidney Int 2021:S0085-2538(21)00581-0. [PMID: 34186057 DOI: 10.1016/j.kint.2021.04.044] [Reference Citation Analysis]
169 de Quadros Onofrio F, Neong E, Adebayo D, Kollmann D, Adeyi OA, Fischer S, Hirschfield GM, Hansen BE, Bhat M, Galvin Z, Lilly LB, Selzner N. Single-Center North American Experience of Liver Transplantation in Autoimmune Hepatitis: Infrequent Indication but Good Outcomes for Patients. J Can Assoc Gastroenterol 2021;4:137-44. [PMID: 34056531 DOI: 10.1093/jcag/gwaa022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Martinelli J, Habes D, Majed L, Guettier C, Gonzalès E, Linglart A, Larue C, Furlan V, Pariente D, Baujard C, Branchereau S, Gauthier F, Jacquemin E, Bernard O. Long-term outcome of liver transplantation in childhood: A study of 20-year survivors. Am J Transplant 2018;18:1680-9. [PMID: 29247469 DOI: 10.1111/ajt.14626] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
171 Hirata M, Yagi S, Shindo T, Yoshizawa A, Kiguchi G, Kaneshiro M, Yurugi K, Miyachi Y, Iwamura S, Yao S, Uemoto S. Donor-dominant one-way matching of human leukocyte antigen-A/B/DR alleles predicts graft-versus-host disease following living donor liver transplantation. Hepatol Res 2021;51:135-48. [PMID: 33034106 DOI: 10.1111/hepr.13579] [Reference Citation Analysis]
172 Fels Elliott DR, Tavakol M, Lucas CH, Sheahon K, Kakar S, Hameed B, Ferrell LD, Gill RM. Clinicopathological features and outcomes of parenchymal rejection in liver transplant biopsies. Histopathology 2020;76:822-31. [PMID: 31894595 DOI: 10.1111/his.14058] [Reference Citation Analysis]
173 Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, Everly MJ. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 2019;69:1273-1286. [PMID: 30229989 DOI: 10.1002/hep.30281] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
174 Yamanashi K, Chen-yoshikawa TF, Hamaji M, Yurugi K, Tanaka S, Yutaka Y, Yamada Y, Nakajima D, Ohsumi A, Date H. Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation. Gen Thorac Cardiovasc Surg 2020;68:142-9. [DOI: 10.1007/s11748-019-01189-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
175 Shi Y, Dong K, Zhang YG, Michel RP, Marcus V, Wang YY, Chen Y, Gao ZH. Sinusoidal endotheliitis as a histological parameter for diagnosing acute liver allograft rejection. World J Gastroenterol 2017; 23(5): 792-799 [PMID: 28223723 DOI: 10.3748/wjg.v23.i5.792] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
176 Takatsuki M, Eguchi S, Yamamoto M, Yamaue H, Takada Y; Japanese Society of Hepato-Biliary-Pancreatic Surgery. The outcomes of thrombotic microangiopathy after liver transplantation: A nationwide survey in Japan. J Hepatobiliary Pancreat Sci 2021. [PMID: 34355533 DOI: 10.1002/jhbp.1032] [Reference Citation Analysis]
177 Osawa I, Ide K, Sakamoto S, Uchida H, Fukuda A, Nishimura N, Haga C, Yoshioka T, Nosaka S, Nakagawa S, Kasahara M. Hematological and biochemical characteristics and diagnostic imaging results in acute T cell-mediated rejection after pediatric liver transplantation. Pediatr Transplant 2021;:e14161. [PMID: 34617637 DOI: 10.1111/petr.14161] [Reference Citation Analysis]
178 Del Bello A, Gaible C, Longlune N, Hebral AL, Esposito L, Gandia P, Kamar N. Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Front Pharmacol 2021;12:602764. [PMID: 34690747 DOI: 10.3389/fphar.2021.602764] [Reference Citation Analysis]
179 Zhang AB, Peng YF, Jia JJ, Nie Y, Zhang SY, Xie HY, Zhou L, Zheng SS. Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation. J Zhejiang Univ Sci B 2019;20:605-12. [PMID: 31168974 DOI: 10.1631/jzus.B1900051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
180 Narumoto S, Sakamoto S, Sasaki K, Hirata Y, Fukuda A, Uchiyama T, Irie R, Yoshioka T, Kasahara M. ABO-incompatible liver transplantation for children under 2 years of age: A case report and a single-center review. Pediatr Transplant 2019;23:e13308. [DOI: 10.1111/petr.13308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Abrol N, Jadlowiec CC, Taner T. Revisiting the liver’s role in transplant alloimmunity. World J Gastroenterol 2019; 25(25): 3123-3135 [PMID: 31333306 DOI: 10.3748/wjg.v25.i25.3123] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
182 Horváth T, Jász DK, Baráth B, Poles MZ, Boros M, Hartmann P. Mitochondrial Consequences of Organ Preservation Techniques during Liver Transplantation. Int J Mol Sci 2021;22:2816. [PMID: 33802177 DOI: 10.3390/ijms22062816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
183 Fischer HP, Goltz D. [Autoimmune liver diseases]. Pathologe 2020;41:444-56. [PMID: 32749523 DOI: 10.1007/s00292-020-00807-7] [Reference Citation Analysis]
184 Ruiz P, Millán O, Ríos J, Díaz A, Sastre L, Colmenero J, Crespo G, Brunet M, Navasa M. MicroRNAs 155-5p, 122-5p, and 181a-5p Identify Patients With Graft Dysfunction Due to T Cell-Mediated Rejection After Liver Transplantation. Liver Transpl 2020;26:1275-86. [PMID: 32615025 DOI: 10.1002/lt.25842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest 2017;127:2492-504. [PMID: 28604384 DOI: 10.1172/JCI90597] [Cited by in Crossref: 83] [Cited by in F6Publishing: 36] [Article Influence: 20.8] [Reference Citation Analysis]
186 Harrington CR, Yang GY, Levitsky J. Advances in Rejection Management: Prevention and Treatment. Clin Liver Dis 2021;25:53-72. [PMID: 33978583 DOI: 10.1016/j.cld.2020.08.003] [Reference Citation Analysis]
187 Borbat AM, Dubova EA, Gaynullina ER, Lishchuk SV. [Protocol for histological examination of liver transplant dysfunction]. Arkh Patol 2019;81:71-3. [PMID: 31851195 DOI: 10.17116/patol20198106171] [Reference Citation Analysis]
188 Levitsky J, Asrani SK, Schiano T, Moss A, Chavin K, Miller C, Guo K, Zhao L, Kandpal M, Bridges N, Brown M, Armstrong B, Kurian S, Demetris AJ, Abecassis M; Clinical Trials in Organ Transplantation - 14 Consortium. Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation. Am J Transplant 2020;20:2173-83. [PMID: 32356368 DOI: 10.1111/ajt.15953] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
189 Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know. J Clin Exp Hepatol 2017;7:358-66. [PMID: 29234201 DOI: 10.1016/j.jceh.2017.10.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
190 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 28.5] [Reference Citation Analysis]
191 Neves Souza L, de Martino RB, Sanchez-fueyo A, Rela M, Dhawan A, O'grady J, Heaton N, Quaglia A. Histopathology of 460 liver allografts removed at retransplantation: A shift in disease patterns over 27 years. Clin Transplant 2018;32:e13227. [DOI: 10.1111/ctr.13227] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
192 Nilles KM, Levitsky J. Donor-Specific Antibodies in Liver Transplantation. Clin Liver Dis (Hoboken) 2020;15:13-6. [PMID: 32104571 DOI: 10.1002/cld.871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
193 Jin YP, Valenzuela NM, Zhang X, Rozengurt E, Reed EF. HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. J Immunol 2018;200:2372-90. [PMID: 29475988 DOI: 10.4049/jimmunol.1701259] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
194 Jia J, Nie Y, Geng L, Li J, Liu J, Peng Y, Huang J, Xie H, Zhou L, Zheng SS. Identification of HO-1 as a novel biomarker for graft acute cellular rejection and prognosis prediction after liver transplantation. Ann Transl Med 2020;8:221. [PMID: 32309368 DOI: 10.21037/atm.2020.01.59] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Taner T. Liver transplantation: Rejection and tolerance: TANER. Liver Transpl 2017;23:S85-8. [DOI: 10.1002/lt.24840] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]